Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...

Michael J. Fox has spent decades navigating Parkinson’s disease while continuing to shape the conversations about the ...

This post is the first in a five-part series summarizing APDA’s recent “Ask the Expert” event on Smart Patients. During the ...

Since its inception in 2000, The Michael J. Fox Foundation has become the world’s largest nonprofit funder of Parkinson’s research, recently marking over $3 billion in total contributions toward ...

Today's FDA approval of tavapadon makes it the first selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease.

A small study found disease-related odor compounds may show up in skin samples, including from the navel, but much larger trials are needed.

Phylo today launched Target Atlas, an agentic target-prioritization app built on Biomni Lab, the company's Integrated Biology Environment. Target Atlas can cut the evidence-gathering behind target ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

Gain Therapeutics’ lead drug candidate rexaceract, formerly known as GT-02287, is in clinical development for the treatment ...

A new study by scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB) in Hyderabad has revealed how viral ...

Newronika received FDA approval of an Investigational Device Exemption, allowing the company to initiate the ADVENT pivotal ...

Research conducted by the Fraunhofer Institute for Integrated Circuits (IIS) in Germany and others has revealed that the ...